Prosonix, (Oxford, UK) leader in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries, are delighted to announce the appointment of Dr Jim Phillips to the key post of Non-Executive Chairman.

Prosonix Ltd (Oxford, UK) is delighted to announce a new agreement for the application of its proprietary ultrasonic particle engineering technology in the pharmaceutical industry. This new agreement has been concluded with Aeropharm (Rudolstadt, Germany) and is concerned with the development and manufacture of a new generation of “difficult-to-make” generic products. According to a recent industry report, the market size for inhaled medicines is expected to rise to $58 billion in 2012. With a significant portion of these revenues available for near term generic substitution, and inhaled drug delivery representing one of the most difficult material science challenges from an equivalence perspective, there is an ideal opportunity to leverage a new ultrasonic particle engineering led approach to generate lasting and significant commercial advantage.

Prosonix Ltd (Oxford, UK), acknowledged leader in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries, have today successfully completed a £5 million total funding round designed to underpin and drive the accelerated future growth plans of the business.

Prosonix Limited (Oxford, UK) and the University of Bath (Bath, UK) are delighted to announce that they have won the Royal Society of Chemistry’s 2006 Team Innovation Award for their novel particle engineering technology Solution, Atomisation and Crystallization by Sonication(SAX^TM). The Royal Society of Chemistry is Europe’s Largest Professional Organisation for Advancing the Chemical Sciences, and one of the worlds oldest and most prestigious scientific institutions.

The University of Bath (Bath, UK) and Prosonix Limited (Oxford, UK) are delighted to announce the signing of an exclusive agreement for the development and commercialisation of the University’s novel particle engineering technology Solution, Atomisation and Crystallization by Sonication (SAX).

Prosonix Ltd (Oxford UK) and UCB SA (Braine l’Alleud, Belgium), are pleased to announce the extension of their Co-Development and Licensing Agreement for the utilization of Prosonix’ proprietary sonocrystallization technology across a range of its pharmaceutical products.

Prosonix Limited (Oxford, UK) is delighted to announce an agreement with the University of Bath (Bath, UK) for the exclusive commercialisation of the University’s unique sonocrystallization particle engineering technology Solution Atomisation and Crystallization by Sonication (SAX^TM). The agreement builds on 18 months of initial collaboration and technology evaluation between the parties.